DANOCRINE
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Jun 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DANOCRINE (danazol) is an oral small-molecule synthetic androgen approved in 1976 for endometriosis and other gynecological conditions. The drug modulates hormonal pathways to suppress ovulation and reduce endometrial tissue proliferation. It represents a legacy therapeutic in a market that has evolved significantly since its original approval.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the DANOCRINE team is likely consolidating operations and prioritizing cost management over growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DANOCRINE offers limited career growth as a legacy product approaching loss of exclusivity under Sanofi's portfolio. Roles on this product are typically focused on defending market share, optimizing costs, and managing the transition to generic or post-exclusivity phases rather than innovation or launch activity.
Brand ManagerField Sales Representative
Worked on DANOCRINE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.